By modulating Ndufa4 expression to influence the metabolic profile and interferon responsiveness of differentiated colonocytes, miR147 emerges as a potential therapeutic target for both IBD and colorectal cancer. The gene discussed is COXFA4; the disease is inflammatory bowel disease.